Solute carrier family 12 member 1 (NKCC2) and Solute carrier family 12 member 3 (NCC) (SLC12A1; SLC12A3)

The target entry refers to two distinct ion transporters: Solute carrier family 12 member 1 (NKCC2) and Solute carrier family 12 member 3 (NCC). NKCC2 is located in the thick ascending limb of the loop of Henle and is responsible for reabsorbing sodium, potassium, and chloride from the tubular fluid (UniProt P55017). NCC is located in the distal convoluted tubule and mediates the reabsorption of sodium and chloride (UniProt P55018). Both proteins are essential for maintaining electrolyte homeostasis and blood pressure (PubMed: 15603714). NKCC2 is the molecular target for loop diuretics like furosemide, which are used to treat edema and hypertension (StatPearls: NBK546656). NCC is the target for thiazide diuretics, such as hydrochlorothiazide, commonly used as first-line therapy for hypertension (StatPearls: NBK532918). Genetic mutations in these transporters cause Bartter syndrome type 1 and Gitelman syndrome, respectively (NIH: Genetics Home Reference). These transporters are critical components of the renal system's ability to concentrate urine and regulate systemic fluid volume.

Other names

NKCC2NCCSLC12A1SLC12A3BSC1TSCBumetanide-sensitive cotransporter 1Thiazide-sensitive cotransporterSodium-potassium-chloride cotransporter 2Sodium-chloride cotransporter

Loop diuretics (e.g., furosemide) inhibit the NKCC2 transporter by competing for the chloride-binding site, preventing the reabsorption of Na+, K+, and Cl-, which leads to increased water excretion (StatPearls: NBK546656). Thiazide diuretics (e.g., hydrochlorothiazide) inhibit the NCC transporter in the distal convoluted tubule by binding to the chloride site, reducing sodium and chloride reabsorption and promoting diuresis (StatPearls: NBK532918).